The Change of Anterior Chamber Parameters with Pentacam(R) after Intravitreal Injection.
10.3341/jkos.2013.54.12.1824
- Author:
Byoung Seon KIM
1
;
Che Ron KIM
;
Seong Jae KIM
;
Yong Seop HAN
;
Seong Wook SEO
;
Ji Myung YOO
;
In Young CHUNG
;
Jong Moon PARK
Author Information
1. Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea. parkjm@gnu.ac.kr
- Publication Type:Original Article
- Keywords:
Anterior chamber parameters;
Intravitreal injection;
Pentacam(R)
- MeSH:
Anterior Chamber*;
Humans;
Intraocular Pressure;
Intravitreal Injections*;
Triamcinolone Acetonide;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2013;54(12):1824-1831
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the changes of anterior chamber parameters and intraocular pressure (IOP) with Pentacam(R) after intravitreal injection. METHODS: A total of 76 eyes of 76 patients received an intravitreal injection of either triamcinolone acetonide (TA) or bevacizumab. Twelve patients were treated with an intravitreal injection of TA 0.1 ml, 16 patients were treated with an intravitreal injection of TA 0.05 ml, while the remaining 48 patients received a bevacizumab 0.05 ml injection. All patients underwent anterior chamber depth, anterior chamber angle, and anterior chamber volume evaluation with Pentacam(R) before and 5 minutes after injection. Additionally, IOP measurements were taken 5 minutes before and 5 minutes, 30 minutes, 1 hour and 1 day after injection. RESULTS: Anterior chamber depth, anterior chamber angle, anterior chamber volume, and IOP changes in patients receiving TA 0.1 ml were 0.4 +/- 0.11 mm, 10.2 +/- 4.1degrees, 33.7 +/- 5.9 mm3 and 18.8 +/- 12.1 mm Hg, respectively. Anterior chamber depth, anterior chamber angle, anterior chamber volume, and IOP changes in patients receiving TA 0.05 ml were -0.01 +/- 0.05 mm, 2.4 +/- 3.2degrees, 5.8 +/- 9.5 mm3 and 4.8 +/- 7.4 mm Hg, respectively. Anterior chamber depth, anterior chamber angle, anterior chamber volume, and IOP changes in patients receiving bevacizumab were 0.28 +/- 0.99 mm, 0.8 +/- 4.0degrees, 7.1 +/- 9.6 mm3 and 5.4 +/- 6.3 mm Hg, respectively. There was a significant difference between TA 0.1 ml and 0.05 ml. However, there was no significant difference between TA 0.05 ml and bevacizumab 0.05 ml. CONCLUSIONS: Because of similar anterior chamber parameters changes after 0.05 ml intravitreal injection with TA or bevacizumab, early period IOP increases due to intravitreal volume expansion. Intravitreal 0.05 ml injections do not require any other procedures for controlling IOP 30 minutes after injection.
